Post-SSRI Sexual Dysfunction (PSSD) is a condition where sexual and emotional side effects from SSRI or SNRI antidepressants persist after the medication is discontinued. Symptoms include genital numbness, anorgasmia, emotional blunting, and reduced libido. The European Medicines Agency formally recognized PSSD in 2019 and mandated updated labelling for all SSRIs and SNRIs sold in Europe.

Does PSSD go away on its own?

For some people PSSD resolves partially or fully over time, but for others it persists for years. A 2021 study by Studt et al. found that 37% of PSSD patients reported no improvement or worsening at follow-up. Duration varies widely — from months to over a decade in documented cases.

Is PSSD a recognised medical condition?

Yes. The European Medicines Agency (EMA) reviewed the evidence in 2019 and concluded that PSSD is a real adverse effect of SSRIs and SNRIs. The EMA mandated that all product information for these drugs include PSSD as a potential persistent adverse effect.

Can psilocybin help with PSSD?

No clinical trials have tested psilocybin specifically for PSSD. However, psilocybin acts as a 5-HT2A agonist and has demonstrated neuroplasticity effects in multiple peer-reviewed studies (Carhart-Harris et al. Nature Medicine 2021; Raval et al. 2021). These mechanisms overlap with the serotonergic systems disrupted in PSSD. According to Shrooomz's research into serotonergic health, this mechanistic overlap makes psilocybin a subject of significant interest in the PSSD community, though direct evidence is currently absent.

What are the main symptoms of PSSD?

The most commonly reported PSSD symptoms are: genital numbness or reduced sensation, anorgasmia (inability to orgasm or significantly reduced orgasm quality), emotional blunting or anhedonia, reduced libido, and erectile dysfunction or vaginal dryness. Cognitive symptoms including brain fog are also reported by a significant subset of patients.

Why don't doctors know about PSSD?

PSSD was not included in prescribing guidelines or medical school curricula until very recently. A landmark 2019 study by Healy et al. documented 62 patients across 23 countries, the majority of whom reported that their doctors dismissed or minimised their symptoms. The EMA's 2019 labelling mandate was a turning point, but awareness in clinical practice remains low.

Post-SSRI Sexual Dysfunction (PSSD): Complete Resource Hub

Q: What causes PSSD?

The exact mechanism is not fully established. Leading hypotheses include persistent 5-HT1A receptor desensitisation, epigenetic changes to serotonin receptor expression, small-fiber neuropathy (supported by a 2022 Finnish biopsy study), and disruption of neuropeptide signalling in genital tissue.

Q: How many people have PSSD?

Prevalence estimates vary widely due to underreporting and lack of systematic screening. Given that approximately 13% of Americans take antidepressants and that sexual side effects during SSRI use are reported in 30–70% of patients, even conservative estimates suggest hundreds of thousands of people may be affected by persistent symptoms after discontinuation.

Post-SSRI Sexual Dysfunction (PSSD) is a condition where sexual and emotional side effects from antidepressants persist after the medication is discontinued. Recognized by the European Medicines Agency, PSSD affects millions worldwide.

Direct Answer: Post-SSRI Sexual Dysfunction (PSSD) is a condition where sexual and emotional side effects from antidepressants persist after the medication is discontinued. Recognized by the European Medicines Agency in 2019, PSSD affects millions worldwide and can include genital numbness, anorgasmia, emotional blunting, and reduced sensation. There is no FDA-approved treatment, but research into serotonergic mechanisms continues to grow.

What Is PSSD?

Post-SSRI Sexual Dysfunction (PSSD) is a condition characterised by the persistence of sexual and emotional side effects from selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) after the medication has been discontinued. Unlike the well-known sexual side effects that occur during antidepressant use — which typically resolve when the drug is stopped — PSSD symptoms continue indefinitely, in some cases for years or decades.

The condition was formally recognised by the European Medicines Agency (EMA) in 2019 following a review of the available evidence. The EMA concluded that PSSD is a real adverse effect and mandated that all product information for SSRIs and SNRIs sold in Europe include PSSD as a potential persistent adverse effect. This was a landmark moment for the millions of patients who had been told their symptoms were psychological or would resolve with time.

Core Symptoms

PSSD presents with a constellation of symptoms that can vary in severity and combination between individuals. The following table summarises the most commonly reported symptoms based on published case series and patient surveys:

Symptom	How Common	Typical Duration	Impact on Quality of Life
Genital numbness / reduced sensation	Most common (>80% in surveys)	Months to years	Severe — affects intimacy and self-image
Anorgasmia / reduced orgasm quality	Very common (>75%)	Months to years	Severe
Emotional blunting / anhedonia	Common (>60%)	Variable	High — affects relationships and motivation
Reduced libido	Common (>65%)	Months to years	Moderate to severe
Erectile dysfunction / vaginal dryness	Common (varies by sex)	Variable	Moderate to severe
Cognitive symptoms / brain fog	Reported by ~40%	Variable	Moderate

The Mechanism: What Happens in the Brain and Body

The precise mechanism of PSSD remains under investigation, but several hypotheses have gained traction in peer-reviewed literature:

1. Persistent 5-HT1A Receptor Desensitisation

SSRIs chronically elevate synaptic serotonin, which leads to compensatory downregulation and desensitisation of 5-HT1A autoreceptors. In most patients this normalises after discontinuation, but in PSSD patients it may persist — maintaining a state of blunted serotonergic signalling that affects both sexual response and emotional processing.

2. Epigenetic Changes to Serotonin Receptor Expression

Chronic SSRI exposure may induce epigenetic modifications (DNA methylation, histone acetylation) that alter the expression of serotonin receptor genes. These changes can outlast the drug's pharmacological presence, potentially explaining why symptoms persist long after plasma levels return to zero.

3. Small-Fiber Neuropathy

A 2022 Finnish study (Heikkinen et al.) performed skin punch biopsies on PSSD patients and found evidence of small-fiber neuropathy — damage to the small sensory nerve fibers responsible for genital sensation. This provides a structural explanation for the genital numbness that is the hallmark symptom of PSSD.

4. Neuropeptide Disruption

SSRIs affect not only serotonin but also neuropeptides including oxytocin, vasopressin, and nitric oxide — all of which play roles in sexual arousal and response. Disruption of these systems may contribute to the multi-dimensional symptom profile of PSSD.

5. Neuroplasticity Impairment

Emerging research suggests that chronic SSRI use may reduce BDNF (brain-derived neurotrophic factor) signalling in certain circuits, impairing the brain's ability to re-establish normal receptor density and connectivity after discontinuation. According to Shrooomz's research into serotonergic health, this neuroplasticity angle is one of the most promising areas for future investigation.

Who Is Affected?

PSSD can affect anyone who has taken an SSRI or SNRI, regardless of dose, duration of use, or the reason for prescribing. Cases have been documented after as few as one or two doses, though longer treatment duration appears to increase risk. The condition affects men and women, and has been reported across all age groups.

Given that approximately 13% of Americans currently take antidepressants (CDC, 2020), and that sexual side effects during SSRI use are reported in 30–70% of patients, even conservative estimates suggest that hundreds of thousands of people in the United States alone may be living with persistent symptoms after discontinuation.

The Research Landscape

Research into PSSD has accelerated since the EMA's 2019 recognition. Key milestones include:

Healy et al. 2019 — Documented 62 patients across 23 countries. The majority reported that their physicians dismissed or minimised their symptoms. This paper was instrumental in the EMA review.
Studt et al. 2021 — Follow-up data showing 37% of PSSD patients reported no improvement or worsening over the observation period, challenging the assumption that PSSD is self-limiting.
Heikkinen et al. 2022 — Finnish biopsy study providing the first histological evidence of small-fiber neuropathy in PSSD patients, suggesting a structural peripheral nervous system component.
Rice et al. 2025 — Qualitative study documenting the "loss of self" theme in PSSD patients, with emotional blunting described as more distressing than the sexual symptoms for many participants.

Psilocybin and PSSD: The Mechanistic Connection

No clinical trials have tested psilocybin specifically for PSSD. However, psilocybin's primary mechanism — 5-HT2A receptor agonism — and its well-documented neuroplasticity effects create a mechanistic overlap with the systems disrupted in PSSD that has attracted significant interest in the research and patient communities.

Carhart-Harris et al. (Nature Medicine, 2021) demonstrated that psilocybin therapy produced greater emotional reconnection and antidepressant effects than escitalopram (an SSRI) in a head-to-head trial. Raval et al. (2021) showed that a single dose of psilocybin increased synaptic density in the prefrontal cortex of rodents within 24 hours. Drewko et al. (2025) confirmed neuroplasticity-promoting effects in human subjects.

These findings do not constitute evidence that psilocybin treats PSSD. They do suggest that psilocybin acts on the same serotonergic and neuroplasticity systems that PSSD disrupts — which is why this intersection is one of the most actively discussed topics in PSSD communities and emerging research.

Explore Shrooomz Botanical Supplements

USA-grown. Third-party tested. Formulated for serotonergic health and neuroplasticity support.

View Our Supplements →

PSSD Resource Hub: All Articles

This hub links to all articles in the Shrooomz PSSD research cluster. Each article covers a specific aspect of the condition with full citations and data tables: